Literature DB >> 23702714

Serum antibodies associated with complex inflammatory bowel disease.

Abdul A Elkadri1, Joanne M Stempak, Thomas D Walters, Simon Lal, Anne M Griffiths, A Hillary Steinhart, Mark S Silverberg.   

Abstract

BACKGROUND: Antibodies to microbial antigens have been associated with specific diagnoses and phenotypes of inflammatory bowel disease. We evaluated the prevalence of pANCA, IgA and IgG anti-Saccharomyces cerevisiae antibodies, anti-OmpC, and anti-flagellin in a large well-defined population of patients with Crohn's disease (CD) and ulcerative colitis (UC) and analyzed for various clinical outcomes.
METHODS: Samples were collected from 391 patients with CD, 207 patients with UC, and 62 healthy controls. Patients were phenotyped using the Montreal classification. Blinded serological analyses were performed for pANCA, IgA and IgG anti-Saccharomyces cerevisiae antibodies, anti-OmpC, and anti-flagellin.
RESULTS: In CD, increasing quantitative levels for antibodies were associated with a younger age of diagnosis, longer disease duration, increased surgeries, ileocolonic and perianal disease, and internal perforating behavior. In UC, they were associated with colectomy. An increasing number of seropositive antibodies in CD was associated with a younger age at diagnosis, increased disease duration, ileocolonic and perianal disease, internal penetrating and stricturing behavior, and increased surgeries. Multivariate analysis confirmed the association of antimicrobial antibodies with features of complicated CD and UC.
CONCLUSIONS: Increased serological markers are associated with a more aggressive CD phenotype and an increased need for colectomy in UC. This raises the possibility for use of these markers in patients at risk of complex disease.

Entities:  

Mesh:

Substances:

Year:  2013        PMID: 23702714     DOI: 10.1097/MIB.0b013e318281f2a1

Source DB:  PubMed          Journal:  Inflamm Bowel Dis        ISSN: 1078-0998            Impact factor:   5.325


  11 in total

1.  A SPECIAL MEETING REVIEW EDITION: Highlights in Anti-Tumor Necrosis Factor Monitoring and Antibody Monitoring From the 2014 DDW Meeting: Digestive Disease Week 2014 May 3-6, 2014 • Chicago, Illinois: Special Reporting on:• Therapeutic Monitoring of Anti-TNF Levels and Antibodies to Predict Response and Achieve Mucosal Healing• Prospective Therapeutic Drug Monitoring and Optimization of Infliximab Maintenance Therapy in IBD• Classification of Non-IBD, Crohn's Disease and Ulcerative Colitis in a Young Patient Population Using a Multi-Marker Diagnostic Panel• Persistence of Antibodies to Infliximab for More Than Two Months Predicts Loss of Response to Infliximab in Inflammatory Bowel Diseases• Pre-Operative Serological Markers May Predict Postoperative Crohn's Disease Recurrence: Results From a Prospective Mono-Centric Trial• Antibodies and Levels of Biologies-Reactive vs Proactive Measurements• Higher 6-Thioguanine Nucleotide Concentrations Are Associated With Higher Trough Levels of Infliximab in Patients on Combination Therapy• The Clinical and Immunological Significance of Low Levels of Infliximab in the Absence of Anti-lnfliximab Antibodies in Patients With IBD• Antibodies to Adalimumab Predict Inflammation in Crohn's Patients on Maintenance Adalimumab Therapy• ATG16L1 Genotype Is Associated With Response to Anti-TNFWith Expert Commentary by:William J. Sandborn, MDProfessor and Chief, Division of Gastroenterology Director, UCSD IBD CenterUC San Diego Health SystemLa Jolla, California.

Authors: 
Journal:  Gastroenterol Hepatol (N Y)       Date:  2014-07

Review 2.  Immune Responses to Intestinal Microbes in Inflammatory Bowel Diseases.

Authors:  Jonathan J Hansen
Journal:  Curr Allergy Asthma Rep       Date:  2015-10       Impact factor: 4.806

3.  Biomarkers of Crohn's Disease to Support the Development of New Therapeutic Interventions.

Authors:  Amy C Porter; Jiri Aubrecht; Chandler Birch; Jonathan Braun; Carolyn Cuff; Suryasarathi Dasgupta; Jeremy D Gale; Robert Hinton; Steven C Hoffmann; Gerard Honig; Bryan Linggi; Marco Schito; Niels Vande Casteele; John-Michael Sauer
Journal:  Inflamm Bowel Dis       Date:  2020-09-18       Impact factor: 5.325

Review 4.  Understanding host-adherent-invasive Escherichia coli interaction in Crohn's disease: opening up new therapeutic strategies.

Authors:  Allison Agus; Sébastien Massier; Arlette Darfeuille-Michaud; Elisabeth Billard; Nicolas Barnich
Journal:  Biomed Res Int       Date:  2014-12-15       Impact factor: 3.411

5.  Neutrophilic Dermatoses in Antineutrophil Cytoplasmic Antibody-Associated Vasculitis: A French Multicenter Study of 17 Cases and Literature Review.

Authors:  Hubert de Boysson; Nicolas Martin Silva; Claire de Moreuil; Antoine Néel; Mathilde de Menthon; Olivier Meyer; David Launay; Christian Pagnoux; Loïc Guillevin; Xavier Puéchal; Boris Bienvenu; Achille Aouba
Journal:  Medicine (Baltimore)       Date:  2016-03       Impact factor: 1.889

6.  Significance of serological markers in the disease course of ulcerative colitis in a prospective clinical cohort of patients.

Authors:  Gyorgy Kovacs; Nora Sipeki; Boglarka Suga; Tamas Tornai; Kai Fechner; Gary L Norman; Zakera Shums; Peter Antal-Szalmas; Maria Papp
Journal:  PLoS One       Date:  2018-03-28       Impact factor: 3.240

7.  PR3-ANCA and panel diagnostics in pediatric inflammatory bowel disease to distinguish ulcerative colitis from Crohn's disease.

Authors:  Michael P Horn; Anna Maria Peter; Franziska Righini Grunder; Alexander B Leichtle; Johannes Spalinger; Susanne Schibli; Christiane Sokollik
Journal:  PLoS One       Date:  2018-12-17       Impact factor: 3.240

8.  Levels of Anti-Citrullinated Protein Antibodies and Rheumatoid Factor, Including IgA Isotypes, and Articular Manifestations in Ulcerative Colitis and Crohn's Disease.

Authors:  Koen M J Janssen; Hilde Hop; Arjan Vissink; Gerard Dijkstra; Menke J de Smit; Elisabeth Brouwer; Johanna Westra
Journal:  Int J Environ Res Public Health       Date:  2020-11-01       Impact factor: 3.390

9.  Gastrointestinal Symptoms and Elevated Levels of Anti-Saccharomyces cerevisiae Antibodies Are Associated with Higher Disease Activity in Colombian Patients with Spondyloarthritis.

Authors:  C Romero-Sánchez; W Bautista-Molano; V Parra; J De Avila; J C Rueda; J M Bello-Gualtero; J Londoño; R Valle-Oñate
Journal:  Int J Rheumatol       Date:  2017-10-29

Review 10.  New Insights into Inflammatory Bowel Diseases from Proteomic and Lipidomic Studies.

Authors:  Serena Longo; Marcello Chieppa; Luca G Cossa; Chiara C Spinelli; Marco Greco; Michele Maffia; Anna M Giudetti
Journal:  Proteomes       Date:  2020-08-10
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.